{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-029320","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2026-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.141813+00:00","generated_at":"2026-05-15T00:22:13.423549+00:00","sec_items":["1.01","2.03","3.02","5.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Senti Biosciences enters $40M convertible note agreement with Celadon; initial $10M tranche","bullets":["Celadon Partners, largest stockholder, commits up to $40M via Senior Secured Convertible Notes; first tranche $10M.","Notes convertible at $0.6261/share with full-ratchet anti-dilution; maturity 6 months from closing with 200% repayment.","Upon conversion, Celadon would own 54.6% of Senti common stock, triggering a change in control.","Proceeds to fund CMC and clinical trials for SENTI-202; potential CVR transaction tied to milestones up to $60M.","Stockholder meeting required by Aug 31, 2026 to approve issuance beyond 19.99% exchange cap."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-029320","json":"https://secwatch.observer/filing/0001628280-26-029320.json","markdown":"https://secwatch.observer/filing/0001628280-26-029320.md","text":"https://secwatch.observer/filing/0001628280-26-029320.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026029320/0001628280-26-029320-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026029320/snti-20260427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:22:13.423549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ec9ae2e478a3435174ae26301f109270cdc90ac","claim":"Senti Biosciences, Inc. incurred convertible notes of $10.0 million with Celadon Partners SPV 24 affiliate at will not bear any interest unless an event of default has occurred maturing six months after the closing date of the Initial Notes.","evidence_excerpt":"the first tranche consists of $10.0 million in aggregate principal amount of Notes that are to be issued (the “Initial Notes”), subject to the satisfaction of certain specified closing conditions","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026029320/0001628280-26-029320-index.htm","confidence":0.9},{"claim_id":"47f6a8646143d7ffd325b6ddcfda7aae39ce944e","claim":"Senti Biosciences, Inc. entered into Securities Purchase Agreement with an entity affiliated with Celadon Partners SPV 24 valued at $40.0 million (effective 2026-04-27).","evidence_excerpt":"On April 27, 2026, Senti Biosciences Holdings, Inc. (the “Company”), Senti Holdings, Inc., a direct, wholly owned subsidiary of the Company (“Senti Holdings”), and Senti Biosciences, Inc., a direct wholly owned subsidiary of Senti Biosciences Holdings (“Senti Biosciences”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with one accredited investor (the “Investor”), pursuant to which Senti Holdings agreed to issue and sell in a private placement up to $40.0 million in aggregate principal amount of its Senior Secured Convertible Notes (the “Notes”) in up to two tranches, subject to the satisfaction of certain specified closing conditions.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026029320/0001628280-26-029320-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-053894","ticker":"TBH","company_name":"Brag House Holdings, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Brag House issues $2.5M convertible notes at 25% OID; proceeds for House of Doge merger","event_type":"debt","sec_items":["1.01","2.03","3.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-053894","json":"https://secwatch.observer/filing/0001213900-26-053894.json","markdown":"https://secwatch.observer/filing/0001213900-26-053894.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1903595/000121390026053894/0001213900-26-053894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1903595/000121390026053894/ea0289773-8k_braghouse.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"the first tranche consists of $10.0 million in aggregate principal amount of Notes that are to be issued (the “Initial Notes”), subject to the satisfaction of certain specified closing conditions","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026029320/0001628280-26-029320-index.htm","comparable_excerpt":"The issuance of the Notes in the aggregate original principal amount of $2,500,000 constitutes the creation of a direct financial obligation of the Company. The Notes bear interest at 12.0% per annum, mature on February 4, 2027","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1903595/000121390026053894/0001213900-26-053894-index.htm"}},{"accession":"0001492691-26-000042","ticker":"KNX","company_name":"Knight-Swift Transportation Holdings Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Knight-Swift closes $1.5B convertible note offering at 1.00% due 2031; proceeds used to repay term loans and revolver","event_type":"debt","sec_items":["1.01","2.03","3.02","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001492691-26-000042","json":"https://secwatch.observer/filing/0001492691-26-000042.json","markdown":"https://secwatch.observer/filing/0001492691-26-000042.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492691/000149269126000042/0001492691-26-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492691/000149269126000042/knx-20260505.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"the first tranche consists of $10.0 million in aggregate principal amount of Notes that are to be issued (the “Initial Notes”), subject to the satisfaction of certain specified closing conditions","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026029320/0001628280-26-029320-index.htm","comparable_excerpt":"On May 8, 2026, Knight-Swift Transportation Holdings Inc. (the \"Company\") completed its previously announced private offering (the \"Offering\") of $1.5 billion aggregate principal amount of 1.00% Convertible Senior Notes due 2031","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1492691/000149269126000042/0001492691-26-000042-index.htm"}},{"accession":"0001104659-26-057128","ticker":"PUMP","company_name":"ProPetro Holding Corp.","filed_at":"2026-05-07T23:59:59+00:00","headline":"ProPetro issues $690M zero-coupon convertible notes due 2031, expands credit facility","event_type":"debt","sec_items":["1.01","2.03","3.02","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057128","json":"https://secwatch.observer/filing/0001104659-26-057128.json","markdown":"https://secwatch.observer/filing/0001104659-26-057128.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680247/000110465926057128/0001104659-26-057128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680247/000110465926057128/tm2613899d1_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"the first tranche consists of $10.0 million in aggregate principal amount of Notes that are to be issued (the “Initial Notes”), subject to the satisfaction of certain specified closing conditions","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026029320/0001628280-26-029320-index.htm","comparable_excerpt":"On May 7, 2026, ProPetro Holding Corp. (the “ Company ”), issued $690 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2031","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1680247/000110465926057128/0001104659-26-057128-index.htm"}},{"accession":"0001104659-26-057138","ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Ocugen completes $115M convertible note offering at 6.75%, repays Avenue loan","event_type":"debt","sec_items":["1.01","1.02","2.02","2.03","3.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057138","json":"https://secwatch.observer/filing/0001104659-26-057138.json","markdown":"https://secwatch.observer/filing/0001104659-26-057138.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926057138/0001104659-26-057138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926057138/tm2613898d1_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"the first tranche consists of $10.0 million in aggregate principal amount of Notes that are to be issued (the “Initial Notes”), subject to the satisfaction of certain specified closing conditions","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026029320/0001628280-26-029320-index.htm","comparable_excerpt":"On May 7, 2026, Ocugen, Inc. (the “Company”) completed its previously announced private offering (the “offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926057138/0001104659-26-057138-index.htm"}},{"accession":"0001104659-26-068944","ticker":"TSEOF","company_name":"Trinseo PLC","filed_at":"2026-06-01T20:23:35+00:00","headline":"Trinseo obtains $142.5M new money DIP financing and $150M AR facility in Chapter 11","event_type":"debt","sec_items":["1.01","2.03","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068944","json":"https://secwatch.observer/filing/0001104659-26-068944.json","markdown":"https://secwatch.observer/filing/0001104659-26-068944.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1519061/000110465926068944/0001104659-26-068944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1519061/000110465926068944/tm2615985d1_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 27, 2026, Senti Biosciences Holdings, Inc. (the “Company”), Senti Holdings, Inc., a direct, wholly owned subsidiary of the Company (“Senti Holdings”), and Senti Biosciences, Inc., a direct wholly owned subsidiary of Senti Biosciences Holdings (“Senti Biosciences”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with one accredited investor (the “Investor”), pursuant to which Senti Holdings agreed to issue and sell in a private placement up to $40.0 million in aggregate principal amount of its Senior Secured Convertible Notes (the “Notes”) in up to two tranches, subject to the satisfaction of certain specified closing conditions.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026029320/0001628280-26-029320-index.htm","comparable_excerpt":"On May 28, 2026, the Company, as parent, Trinseo NA Finance LLC, as holdings, Trinseo Luxco Finance SPV S.à r.l. and Trinseo NA Finance SPV LLC (together, the “ SHC Borrowers ”), as borrowers, the guarantors party thereto from time to time, the lenders party thereto from time to time (the “ SHC DIP Lenders ”), and Alter Domus (US) LLC, as administrative agent and collateral agent, entered into a Senior Secured Super-Priority Debtor-In-Possession HoldCo Credit Agreement (the “ Super-Holdco DIP Credit Agreement ”), providing for a senior secured super-priority priming term loan debtor-in-possession credit facility in an aggregate principal amount of $157.5 million (the “ Super-Holdco DIP Facility ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1519061/000110465926068944/0001104659-26-068944-index.htm"}},{"accession":"0001104659-26-056748","ticker":null,"company_name":"ACURA PHARMACEUTICALS, INC","filed_at":"2026-05-07T23:59:59+00:00","headline":"Acura's debt to related party grows to $10.3M; warns of possible shutdown without new financing by May-end","event_type":"debt","sec_items":["1.01","2.01","2.03","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: debt_financing","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-056748","json":"https://secwatch.observer/filing/0001104659-26-056748.json","markdown":"https://secwatch.observer/filing/0001104659-26-056748.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/786947/000110465926056748/0001104659-26-056748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/786947/000110465926056748/tm2613771d1_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"the first tranche consists of $10.0 million in aggregate principal amount of Notes that are to be issued (the “Initial Notes”), subject to the satisfaction of certain specified closing conditions","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026029320/0001628280-26-029320-index.htm","comparable_excerpt":"On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465926056748/0001104659-26-056748-index.htm"}},{"accession":"0001193125-26-215654","ticker":"ACH","company_name":"ACCENDRA HEALTH INC/VA/","filed_at":"2026-05-11T23:59:59+00:00","headline":"Accendra Health launches $326.25M 9% first lien notes, $300M revolver, and exchange offers for existing notes","event_type":"debt","sec_items":["1.01","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-215654","json":"https://secwatch.observer/filing/0001193125-26-215654.json","markdown":"https://secwatch.observer/filing/0001193125-26-215654.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/75252/000119312526215654/0001193125-26-215654-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/75252/000119312526215654/d135857d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 27, 2026, Senti Biosciences Holdings, Inc. (the “Company”), Senti Holdings, Inc., a direct, wholly owned subsidiary of the Company (“Senti Holdings”), and Senti Biosciences, Inc., a direct wholly owned subsidiary of Senti Biosciences Holdings (“Senti Biosciences”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with one accredited investor (the “Investor”), pursuant to which Senti Holdings agreed to issue and sell in a private placement up to $40.0 million in aggregate principal amount of its Senior Secured Convertible Notes (the “Notes”) in up to two tranches, subject to the satisfaction of certain specified closing conditions.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026029320/0001628280-26-029320-index.htm","comparable_excerpt":"On May 11, 2026, Accendra Health, Inc. (the “ Company ”) entered into a Commitment and Consent Letter (the “ Commitment Letter ”) with certain institutions that are (a)(i) holders of the Company’s 4.500% Senior Notes due 2029 (the “ 2029 Notes ”) and 6.625% Senior Notes due 2030 (the “ 2030 Notes ” and, together with the 2029 Notes, the “ Existing Notes ”), collectively holding approximately all of the outstanding principal amount of the 2029 Notes and approximately 83% of the outstanding principal amount of the 2030 Notes as of May 11, 2026 and (ii) lenders under the Company’s existing Term Loan Credit Agreement (as defined below) (collectively, the “ Commitment and Consenting Parties ” and each, a “ Commitment and Consenting Party ”), (b) certain lenders under the Company’s existing Term Loan Credit Agreement consenting solely with respect to the Term B-1 Term Loan Consent (as defined below) (the “ Term B-1 Term Loan Consenting Parties ”) and (c) all lenders under the Company’s Exist","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/75252/000119312526215654/0001193125-26-215654-index.htm"}},{"accession":"0001493152-26-021718","ticker":"WGRX","company_name":"Wellgistics Health, Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Wellgistics Health subsidiary enters forbearance agreement on $1.77M debt","event_type":"debt","sec_items":["1.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-021718","json":"https://secwatch.observer/filing/0001493152-26-021718.json","markdown":"https://secwatch.observer/filing/0001493152-26-021718.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2030763/000149315226021718/0001493152-26-021718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2030763/000149315226021718/form8-k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 27, 2026, Senti Biosciences Holdings, Inc. (the “Company”), Senti Holdings, Inc., a direct, wholly owned subsidiary of the Company (“Senti Holdings”), and Senti Biosciences, Inc., a direct wholly owned subsidiary of Senti Biosciences Holdings (“Senti Biosciences”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with one accredited investor (the “Investor”), pursuant to which Senti Holdings agreed to issue and sell in a private placement up to $40.0 million in aggregate principal amount of its Senior Secured Convertible Notes (the “Notes”) in up to two tranches, subject to the satisfaction of certain specified closing conditions.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026029320/0001628280-26-029320-index.htm","comparable_excerpt":"On May 1, 2026, Wellgistics, LLC (“Wellgistics”), a wholly owned subsidiary of Wellgistics Health, Inc. (the “Company”), entered into an Acknowledgment of Indebtedness, Forbearance and Repayment Agreement (the “Forbearance Agreement”) with Marco Capital, Inc. (“MCI”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030763/000149315226021718/0001493152-26-021718-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}